Vor Biopharma’s (VOR) “Buy” Rating Reaffirmed at HC Wainwright

Vor Biopharma (NYSE:VOR)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $17.50 price objective on the stock.

Other equities research analysts have also issued reports about the stock. Barclays lowered their target price on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. JMP Securities reissued a “market outperform” rating and set a $12.00 target price on shares of Vor Biopharma in a research note on Friday, September 6th. Finally, Robert W. Baird reduced their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $11.36.

Vor Biopharma Stock Performance

NYSE:VOR opened at $0.83 on Friday. Vor Biopharma has a one year low of $0.63 and a one year high of $3.14. The firm has a market cap of $57.05 million, a price-to-earnings ratio of -0.48 and a beta of -0.40. The firm’s fifty day moving average is $0.80 and its two-hundred day moving average is $1.08.

Vor Biopharma (NYSE:VOR) last posted its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). As a group, equities research analysts predict that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently bought and sold shares of VOR. Vanguard Group Inc. lifted its stake in Vor Biopharma by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after purchasing an additional 69,436 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Vor Biopharma in the 1st quarter worth approximately $126,000. Renaissance Technologies LLC lifted its stake in Vor Biopharma by 48.0% in the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after purchasing an additional 160,642 shares in the last quarter. Hsbc Holdings PLC lifted its stake in Vor Biopharma by 177.0% in the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after purchasing an additional 31,333 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Vor Biopharma in the 2nd quarter worth approximately $53,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.